NASDAQ:SYBX - Synlogic Stock Price, Forecast & News

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Synlogic's stock reverse split before market open on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

Synlogic Inc (NASDAQ:SYBX) released its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.39) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.48) by $0.09. The biotechnology company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.46 million. Synlogic had a negative net margin of 4,574.82% and a negative return on equity of 34.49%. View Synlogic's Earnings History.

Synlogic is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Synlogic.

7 brokerages have issued 1-year price objectives for Synlogic's stock. Their forecasts range from $2.00 to $25.00. On average, they anticipate Synlogic's share price to reach $14.17 in the next year. This suggests a possible upside of 587.7% from the stock's current price. View Analyst Price Targets for Synlogic.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synlogic.

Press coverage about SYBX stock has trended very negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Synlogic earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Synlogic.

Synlogic saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,520,000 shares, an increase of 7.8% from the January 15th total of 1,410,000 shares. Based on an average daily volume of 474,400 shares, the short-interest ratio is currently 3.2 days. Approximately 8.6% of the company's shares are sold short. View Synlogic's Current Options Chain.

Some companies that are related to Synlogic include Kamada (KMDA), AMAG Pharmaceuticals (AMAG), Gemphire Therapeutics (GEMP), Bicycle Therapeutics (BCYC), BIOFRONTERA AG/ADR (BFRA), Seres Therapeutics (MCRB), Aduro BioTech (ADRO), Kalvista Pharmaceuticals (KALV), VBI Vaccines (VBIV), Geron (GERN), IVERIC bio (ISEE), Ocular Therapeutix (OCUL), Sol Gel Technologies (SLGL), Kala Pharmaceuticals (KALA) and Theratechnologies (THERF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Anavex Life Sciences (AVXL) and Progenics Pharmaceuticals (PGNX).

Synlogic's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.93%), State Street Corp (0.92%), Geode Capital Management LLC (0.78%), Bank of New York Mellon Corp (0.39%), Jacobs Levy Equity Management Inc. (0.31%) and Oxford Asset Management LLP (0.24%). Company insiders that own Synlogic stock include Paul Francis Miller and Richard P Shea. View Institutional Ownership Trends for Synlogic.

SYBX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp. View Insider Buying and Selling for Synlogic.

SYBX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Oxford Asset Management LLP, Bank of New York Mellon Corp, Geode Capital Management LLC, Virtu Financial LLC, Connor Clark & Lunn Investment Management Ltd. and Goldman Sachs Group Inc.. View Insider Buying and Selling for Synlogic.

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYBX stock can currently be purchased for approximately $2.06.

Synlogic has a market capitalization of $66.52 million and generates $2.52 million in revenue each year. The biotechnology company earns $-48,440,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. Synlogic employs 74 workers across the globe.View Additional Information About Synlogic.

The official website for Synlogic is http://www.synlogictx.com/.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]